Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 109 results for embolism

  1. Endovascular stent insertion for intracranial atherosclerotic disease (IPG429)

    Evidence-based recommendations on endovascular stent insertion for intracranial atherosclerotic disease. This involves inflating a balloon catheter inserted into an artery in the arm or leg, and positioning a stent in the narrowing to maintain improved blood flow.

    Interventional procedures guidance
    Published
    23 July 2012
    View recommendations

    Sections for IPG429

  2. Direct oral anticoagulants for people with lower limb immobilisation:- What is the clinical and cost effectiveness of direct oral anticoagulants for preventing VTE in people with lower limb immobilisation?

    reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other details

    Research recommendation
    Published
    15 November 2018

  3. Dose strategies for people who are obese:- What is the clinical and cost effectiveness of weight-based dose-adjustment strategies of lowmolecular-weight heparin (LMWH) compared with fixed-dose strategies of LMWH for preventing VTE in people who are very obese (BMI over 35) who are admitted to hospital or having day procedures (including surgery and chemotherapy)?

    reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other details

    Research recommendation
    Published
    15 November 2018

  4. Risk assessment:- What is the accuracy of individual risk assessment tools in predicting the risk of venousthromboembolism (VTE) and risk of bleeding in people admitted to hospital?

    reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism Number NG89 Date issued March 2018 Other details

    Research recommendation
    Published
    15 November 2018

  5. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245)

    Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after total hip or knee replacement in adults.

    Technology appraisal guidance
    Published
    25 January 2012
    View recommendations

    Sections for TA245

  6. pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms (MIB222)

    NICE has developed a medtech innovation briefing (MIB) on pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms .

    Medtech innovation briefing
    Published
    11 August 2020

  7. PLASMA system with button electrode for electrovaporisation of the prostate (MIB274)

    NICE has developed a medtech innovation briefing (MIB) on PLASMA system with button electrode for electrovaporisation of the prostate .

    Medtech innovation briefing
    Published
    31 August 2021

  8. Chronic heart failure in adults: diagnosis and management (NG106)

    This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.

    NICE guideline
    Published
    12 September 2018
    View recommendations

    Sections for NG106

  9. Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies (TA171)

    Evidence-based recommendations on lenalidomide (Revlimid) for treating multiple myeloma in adults who have had at least 2 prior therapies.

    Technology appraisal guidance
    Last updated
    26 June 2019
    View recommendations

    Sections for TA171

  10. WoundExpress to manage lower leg wounds (MIB261)

    NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .

    Medtech innovation briefing
    Published
    1 June 2021

  11. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) (DG14)

    Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available

    Diagnostics guidance
    Last updated
    19 December 2017
    View recommendations

    Sections for DG14

  12. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at high risk

    such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 14-17 for more information and diagrams...

  13. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

    Evidence summary
    Published
    10 February 2015

  14. Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke (DG41)

    Evidence-based recommendations on implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke

    Diagnostics guidance
    Published
    2 September 2020
    View recommendations

    Sections for DG41

  15. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at moderately increased risk

    such as deep vein thrombosis (DVT) or a blood clot in the lungs (pulmonary embolism)? See pages 14-17 for more information and diagrams...